COVAXIN showed 77.8 per cent efficacy against symptomatic COVID-19: Lancet Study

The Phase-III trial Efficacy and Safety data of COVAXIN got published in the prestigious medical journal The Lancet. The safety profile of Bharat Biotech’s COVAXIN has now been well-established, it showed 77.8 per cent efficacy against symptomatic COVID-19.



source https://www.jagranjosh.com/current-affairs/covaxin-showed-778-per-cent-efficacy-against-symptomatic-covid19-lancet-study-1636789324-1

Comments

Check These Popular Posts